SIK2/3
Assets acting on this target.
- Class
- Oral SIK2/3 inhibitor
Assets acting on this target.
4 of 4 assets (4 discontinued)
| Drug | Owner | Mechanism | Indication | Reached | Why it stopped | Source |
|---|---|---|---|---|---|---|
| GLPG3970 | Lakefront Biotherapeutics NV | SIK2/3 | Rheumatoid Arthritis | Ph 2 | StrategicGLPG3970's rheumatoid arthritis trial completed in 2021, but Galapagos terminated the drug's parallel Sjögren's Syndrome and systemic lupus erythematosus programs the same year on explicit sponsor/business-decision grounds, and no GLPG3970 trial of any kind (RA or otherwise) has been registered since 2021, indicating the whole program was shelved. | source ↗ |
| GLPG3970 | Lakefront Biotherapeutics NV | SIK2/3 | Ulcerative Colitis | Ph 2 | The UC phase 2 completed in 2021 with no later GLPG3970 UC study; the roster profile records a March 2022 company-wide program discontinuation, but no independent source was opened this session, so the status mirrors the prior v2 curations as unresolved. | source ↗ |
| GLPG3970 | Lakefront Biotherapeutics NV | SIK2/3 | Psoriasis | Ph 1 | EfficacyGalapagos discontinued the entire GLPG3970 (SIK2/3 inhibitor) program in March 2022 after its Phase 2 proof-of-concept studies, including psoriasis, failed to clearly demonstrate efficacy over placebo. | source ↗ |
| GLPG3970 | Lakefront Biotherapeutics NV | SIK2/3 | Systemic Lupus Erythematosus | Ph 1 | The SLE study TAPINOMA (NCT04700267, Phase 1b, randomized double-blind placebo-controlled, 12 weeks) was terminated on 2021-10-06; ClinicalTrials.gov records whyStopped as 'Study stopped on business grounds'. Galapagos NV's Form 20-F for FY2021 states: 'Although we will not progress GLPG3970 into clinical development, the study results are an essential part of the broad evidence package that we are assembling on our SIK program.' No GLPG3970 study of any kind has been registered since 2021. | source ↗ |